Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

227 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.
Di Bartolomeo M, Niger M, Morano F, Corallo S, Antista M, Tamberi S, Lonardi S, Di Donato S, Berardi R, Scartozzi M, Cardellino GG, Di Costanzo F, Rimassa L, Luporini AG, Longarini R, Zaniboni A, Bertolini A, Tomasello G, Pinotti G, Scagliotti G, Tortora G, Bonetti A, Spallanzani A, Frassineti GL, Tassinari D, Giuliani F, Cinieri S, Maiello E, Verusio C, Bracarda S, Catalano V, Basso M, Ciuffreda L, De Vita F, Parra HS, Fornaro L, Caporale M, de Braud F, Pietrantonio F. Di Bartolomeo M, et al. Among authors: bracarda s. BMC Cancer. 2019 Mar 29;19(1):283. doi: 10.1186/s12885-019-5498-3. BMC Cancer. 2019. PMID: 30922323 Free PMC article. Clinical Trial.
Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research.
Roila F, Tonato M, Basurto C, Picciafuoco M, Bracarda S, Donati D, Malacarne P, Monici L, Di Costanzo F, Patoia L, et al. Roila F, et al. Among authors: bracarda s. J Clin Oncol. 1989 Nov;7(11):1693-700. doi: 10.1200/JCO.1989.7.11.1693. J Clin Oncol. 1989. PMID: 2681556 Clinical Trial.
Cancer of the prostate.
Bracarda S, de Cobelli O, Greco C, Prayer-Galetti T, Valdagni R, Gatta G, de Braud F, Bartsch G. Bracarda S, et al. Crit Rev Oncol Hematol. 2005 Dec;56(3):379-96. doi: 10.1016/j.critrevonc.2005.03.010. Crit Rev Oncol Hematol. 2005. PMID: 16310371 Review.
Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial.
Bracarda S, Bellmunt J, Melichar B, Négrier S, Bajetta E, Ravaud A, Sneller V, Escudier B. Bracarda S, et al. BJU Int. 2011 Jan;107(2):214-9. doi: 10.1111/j.1464-410X.2010.09707.x. Epub 2010 Oct 13. BJU Int. 2011. PMID: 20942831 Clinical Trial.
Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials.
Cuppone F, Bria E, Giannarelli D, Vaccaro V, Milella M, Nisticò C, Ruggeri EM, Sperduti I, Bracarda S, Pinnarò P, Lanzetta G, Muti P, Cognetti F, Carlini P. Cuppone F, et al. Among authors: bracarda s. BMC Cancer. 2010 Dec 9;10:675. doi: 10.1186/1471-2407-10-675. BMC Cancer. 2010. PMID: 21143897 Free PMC article.
Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY).
Bracarda S, Porta C, Boni C, Santoro A, Mucciarini C, Pazzola A, Cortesi E, Gasparro D, Labianca R, Di Costanzo F, Falcone A, Cinquini M, Caserta C, Paglino C, De Angelis V. Bracarda S, et al. Eur Urol. 2013 Feb;63(2):254-61. doi: 10.1016/j.eururo.2012.08.027. Epub 2012 Aug 23. Eur Urol. 2013. PMID: 22964169 Clinical Trial.
227 results